FROZENFLAME
9 months ago
Nice !
We ended 2023 with more than $100 million in cash, restricted cash, cash equivalents and investments. Based on our current cash position and operational plans, we believe our financial resources are sufficient to fund the Companyβs operations through the filing of a Biologics License Application (BLA) for efzofitimod in pulmonary sarcoidosis."
$LIFE